Oral contraceptives and risk of ovarian and breast cancers inBRCAmutation carriers: a meta-analysis

New Strategies in Ovarian Cancer: Uptake and Experience of Women at High Risk of Ovarian Cancer Who Are Considering Risk-Reducing Salpingo-Oophorectomy

(2010) S. M. Miller et al.   CLINICAL CANCER RESEARCH

Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: A meta-analysis

(2010) S. Iodice et al.   EUROPEAN JOURNAL OF CANCER

Tubal ligation and the risk of ovarian cancer: review and meta-analysis

(2010) D. Cibula et al.   HUMAN REPRODUCTION UPDATE

Hormonal contraception and risk of cancer

(2010) D. Cibula et al.   HUMAN REPRODUCTION UPDATE

Reproductive and Hormonal Factors, and Ovarian Cancer Risk for BRCA1 and BRCA2 Mutation Carriers: Results from the International BRCA1/2 Carrier Cohort Study

(2009) A. C. Antoniou et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Uptake of Risk-Reducing Surgery in Unaffected Women at High Risk of Breast and Ovarian Cancer Is Risk, Age, and Time Dependent

(2009) D. G. R. Evans et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Oral Contraceptive Use and BRCA Penetrance: A Case-Only Study

(2009) P. Pasanisi et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Meta-analysis of Risk Reduction Estimates Associated With Risk-Reducing Salpingo-oophorectomy in BRCA1 or BRCA2 Mutation Carriers

(2009) T. R. Rebbeck et al.   JNCI-Journal of the National Cancer Institute

Effect of Reproductive Factors and Oral Contraceptives on Breast Cancer Risk in BRCA1/2 Mutation Carriers and Noncarriers: Results from a Population-Based Study

(2008) E. Lee et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Oral Contraceptives, Postmenopausal Hormones, and Risk of Asynchronous Bilateral Breast Cancer: The WECARE Study Group

(2008) Jane C. Figueiredo et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical and Pathologic Characteristics of Patients WithBRCA-Positive andBRCA-Negative Breast Cancer

(2008) Deann P. Atchley et al.   JOURNAL OF CLINICAL ONCOLOGY

Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23 257 women with ovarian cancer and 87 303 controls

(2008)   LANCET

Oral contraceptives, salpingo-oophorectomy and hormone replacement therapy in BRCA1–2 mutation carriers

(2008) N. Biglia et al.   MATURITAS